Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 382

1.

A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma.

Chan WK, Kang S, Youssef Y, Glankler EN, Barrett ER, Carter AM, Ahmed EH, Prasad A, Chen L, Zhang J, Benson DM, Caligiuri MA, Yu J.

Cancer Immunol Res. 2018 May 16. pii: canimm.0649.2017. doi: 10.1158/2326-6066.CIR-17-0649. [Epub ahead of print]

PMID:
29769244
2.

Dependence of innate lymphoid cell 1 development on NKp46.

Wang Y, Dong W, Zhang Y, Caligiuri MA, Yu J.

PLoS Biol. 2018 Apr 27;16(4):e2004867. doi: 10.1371/journal.pbio.2004867. eCollection 2018 Apr.

3.

Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.

Kim Y, Yoo JY, Lee TJ, Liu J, Yu J, Caligiuri MA, Kaur B, Friedman A.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):4927-4932. doi: 10.1073/pnas.1715295115. Epub 2018 Apr 23.

PMID:
29686060
4.

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells.

Wang Y, Zhang Y, Hughes T, Zhang J, Caligiuri MA, Benson DM, Yu J.

Clin Cancer Res. 2018 Apr 17. pii: clincanres.3117.2017. doi: 10.1158/1078-0432.CCR-17-3117. [Epub ahead of print]

PMID:
29666301
5.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
6.

Complete and durable responses in Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab and Dexamethasone.

Dugan JP, Haverkos BM, Villagomez L, Martin L, Lustberg ME, Patton JT, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth JD, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA.

Clin Cancer Res. 2018 Apr 9. pii: clincanres.2685.2017. doi: 10.1158/1078-0432.CCR-17-2685. [Epub ahead of print]

PMID:
29632007
7.

Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials.

Dalton WS, Sullivan D, Ecsedy J, Caligiuri MA.

Clin Pharmacol Ther. 2018 Mar 23. doi: 10.1002/cpt.1051. [Epub ahead of print]

PMID:
29570791
8.

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.

Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum W.

Haematologica. 2018 Mar 22. pii: haematol.2017.186890. doi: 10.3324/haematol.2017.186890. [Epub ahead of print]

9.

Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells.

Dai HS, Caligiuri MA.

Front Immunol. 2018 Feb 12;9:183. doi: 10.3389/fimmu.2018.00183. eCollection 2018. Review.

10.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

PMID:
29431743
11.

Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development.

Victor AR, Weigel C, Scoville SD, Chan WK, Chatman K, Nemer MM, Mao C, Young KA, Zhang J, Yu J, Freud AG, Oakes CC, Caligiuri MA.

J Immunol. 2018 Jan 15;200(2):565-572. doi: 10.4049/jimmunol.1701128. Epub 2017 Dec 11.

PMID:
29229679
12.

Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.

Kohnken R, Wen J, Mundy-Bosse B, McConnell K, Keiter A, Grinshpun L, Hartlage A, Yano M, McNeil B, Chakravarti N, William B, Bradner JE, Caligiuri MA, Porcu P, Mishra A.

Blood. 2018 Feb 15;131(7):771-781. doi: 10.1182/blood-2017-09-805663. Epub 2017 Nov 27.

PMID:
29180399
13.

The Broad Spectrum of Human Natural Killer Cell Diversity.

Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA.

Immunity. 2017 Nov 21;47(5):820-833. doi: 10.1016/j.immuni.2017.10.008. Review.

PMID:
29166586
14.

Addressing Disparities: The 10th Anniversary of the AACR Cancer Health Disparities Conference.

Caligiuri MA.

Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1359. doi: 10.1158/1055-9965.EPI-17-0670. No abstract available.

PMID:
28864452
15.

IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB.

Victor AR, Nalin AP, Dong W, McClory S, Wei M, Mao C, Kladney RD, Youssef Y, Chan WK, Briercheck EL, Hughes T, Scoville SD, Pitarresi JR, Chen C, Manz S, Wu LC, Zhang J, Ostrowski MC, Freud AG, Leone GW, Caligiuri MA, Yu J.

J Immunol. 2017 Oct 1;199(7):2333-2342. doi: 10.4049/jimmunol.1601554. Epub 2017 Aug 25.

PMID:
28842466
16.

MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions.

Campbell AR, Duggan MC, Suarez-Kelly LP, Bhave N, Opheim KS, McMichael EL, Trikha P, Parihar R, Luedke E, Lewis A, Yung B, Lee R, Raulet D, Tridandapani S, Groh V, Yu L, Yildiz V, Byrd JC, Caligiuri MA, Carson WE 3rd.

Cancer Immunol Res. 2017 Sep;5(9):778-789. doi: 10.1158/2326-6066.CIR-16-0005. Epub 2017 Jul 19.

17.

The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells.

Dai HS, Griffin N, Bolyard C, Mao HC, Zhang J, Cripe TP, Suenaga T, Arase H, Nakano I, Chiocca EA, Kaur B, Yu J, Caligiuri MA.

Immunity. 2017 Jul 18;47(1):159-170.e10. doi: 10.1016/j.immuni.2017.06.019.

PMID:
28723548
18.

Ibrutinib treatment improves T cell number and function in CLL patients.

Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC.

J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17.

19.

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.

Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE 3rd.

Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447. doi: 10.1007/s00262-017-2038-3. Epub 2017 Jul 7.

PMID:
28688082
20.

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.

Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang ES, Mrózek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4641-E4647. doi: 10.1073/pnas.1703142114. Epub 2017 May 22.

21.

Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia.

Yip BH, Tsai CT, Rane JK, Vetharoy W, Anguita E, Dong S, Caligiuri MA, So CWE.

Haematologica. 2017 Aug;102(8):e300-e304. doi: 10.3324/haematol.2016.161406. Epub 2017 May 18. No abstract available.

22.

Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.

Chen L, Mao H, Zhang J, Chu J, Devine S, Caligiuri MA, Yu J.

Leukemia. 2017 Aug;31(8):1830-1834. doi: 10.1038/leu.2017.147. Epub 2017 May 12. No abstract available.

23.

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.

Papaioannou D, Nicolet D, Volinia S, Mrózek K, Yan P, Bundschuh R, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld AK, Orwick SJ, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD.

Haematologica. 2017 Aug;102(8):1391-1400. doi: 10.3324/haematol.2017.166215. Epub 2017 May 4.

24.

Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells.

Scoville SD, Freud AG, Caligiuri MA.

Front Immunol. 2017 Mar 27;8:360. doi: 10.3389/fimmu.2017.00360. eCollection 2017.

25.

Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.

Teng KY, Han J, Zhang X, Hsu SH, He S, Wani NA, Barajas JM, Snyder LA, Frankel WL, Caligiuri MA, Jacob ST, Yu J, Ghoshal K.

Mol Cancer Ther. 2017 Feb;16(2):312-322. doi: 10.1158/1535-7163.MCT-16-0124. Epub 2016 Dec 15.

26.

Biallelic mutations in IRF8 impair human NK cell maturation and function.

Mace EM, Bigley V, Gunesch JT, Chinn IK, Angelo LS, Care MA, Maisuria S, Keller MD, Togi S, Watkin LB, LaRosa DF, Jhangiani SN, Muzny DM, Stray-Pedersen A, Coban Akdemir Z, Smith JB, Hernández-Sanabria M, Le DT, Hogg GD, Cao TN, Freud AG, Szymanski EP, Savic S, Collin M, Cant AJ, Gibbs RA, Holland SM, Caligiuri MA, Ozato K, Paust S, Doody GM, Lupski JR, Orange JS.

J Clin Invest. 2017 Jan 3;127(1):306-320. doi: 10.1172/JCI86276. Epub 2016 Nov 28.

27.

BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.

Bolyard C, Meisen WH, Banasavadi-Siddegowda Y, Hardcastle J, Yoo JY, Wohleb ES, Wojton J, Yu JG, Dubin S, Khosla M, Xu B, Smith J, Alvarez-Breckenridge C, Pow-Anpongkul P, Pichiorri F, Zhang J, Old M, Zhu D, Van Meir EG, Godbout JP, Caligiuri MA, Yu J, Kaur B.

Clin Cancer Res. 2017 Apr 1;23(7):1809-1819. doi: 10.1158/1078-0432.CCR-16-1818. Epub 2016 Nov 9.

28.

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz BS, Relation T, Lee TJ, Lotze MT, Yu JG, Zhang J, Croce CM, Yu J, Caligiuri MA, Old M, Kaur B.

Clin Cancer Res. 2016 Nov 1;22(21):5265-5276. Epub 2016 Jul 7. Erratum in: Clin Cancer Res. 2017 Mar 1;23 (5):1359-1360.

29.

MicroRNA-29b mediates altered innate immune development in acute leukemia.

Mundy-Bosse BL, Scoville SD, Chen L, McConnell K, Mao HC, Ahmed EH, Zorko N, Harvey S, Cole J, Zhang X, Costinean S, Croce CM, Larkin K, Byrd JC, Vasu S, Blum W, Yu J, Freud AG, Caligiuri MA.

J Clin Invest. 2016 Dec 1;126(12):4404-4416. doi: 10.1172/JCI85413. Epub 2016 Oct 24.

30.

E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.

Park IK, Blum W, Baker SD, Caligiuri MA.

Leukemia. 2017 Feb;31(2):502-505. doi: 10.1038/leu.2016.293. Epub 2016 Oct 24. No abstract available.

31.

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma.

Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S181-S190.e4. doi: 10.1016/j.clml.2016.02.014.

32.

Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.

Mishra A, La Perle K, Kwiatkowski S, Sullivan LA, Sams GH, Johns J, Curphey DP, Wen J, McConnell K, Qi J, Wong H, Russo G, Zhang J, Marcucci G, Bradner JE, Porcu P, Caligiuri MA.

Cancer Discov. 2016 Sep;6(9):986-1005. doi: 10.1158/2159-8290.CD-15-1297. Epub 2016 Jul 15.

33.

NKp80 Defines a Critical Step during Human Natural Killer Cell Development.

Freud AG, Keller KA, Scoville SD, Mundy-Bosse BL, Cheng S, Youssef Y, Hughes T, Zhang X, Mo X, Porcu P, Baiocchi RA, Yu J, Carson WE 3rd, Caligiuri MA.

Cell Rep. 2016 Jul 12;16(2):379-391. doi: 10.1016/j.celrep.2016.05.095. Epub 2016 Jun 30.

34.

Obesity, Inflammation, and Cancer.

Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA.

Annu Rev Pathol. 2016 May 23;11:421-49. doi: 10.1146/annurev-pathol-012615-044359. Review.

PMID:
27193454
35.

A Progenitor Cell Expressing Transcription Factor RORγt Generates All Human Innate Lymphoid Cell Subsets.

Scoville SD, Mundy-Bosse BL, Zhang MH, Chen L, Zhang X, Keller KA, Hughes T, Chen L, Cheng S, Bergin SM, Mao HC, McClory S, Yu J, Carson WE 3rd, Caligiuri MA, Freud AG.

Immunity. 2016 May 17;44(5):1140-50. doi: 10.1016/j.immuni.2016.04.007. Epub 2016 May 10.

36.

Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype.

Xiao R, Bergin SM, Huang W, Slater AM, Liu X, Judd RT, Lin ED, Widstrom KJ, Scoville SD, Yu J, Caligiuri MA, Cao L.

Cancer Immunol Res. 2016 Jun;4(6):488-497. doi: 10.1158/2326-6066.CIR-15-0297. Epub 2016 Apr 4.

37.

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X, Groh V, Whitman SP, Konopitzky R, Kössl C, Bucci D, Lucas DM, Yu J, Caligiuri MA, Blum W, Adam PJ, Borges E, Rueter B, Heider KH, Marcucci G, Muthusamy N.

Blood. 2016 Jun 9;127(23):2879-89. doi: 10.1182/blood-2015-11-680546. Epub 2016 Mar 24.

38.

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, Harrington B, Old M, Reiff S, Mace T, Tridandapani S, Muthusamy N, Caligiuri MA, Byrd JC, Carson WE 3rd.

Cancer Res. 2016 Apr 15;76(8):2125-36. doi: 10.1158/0008-5472.CAN-15-1490. Epub 2016 Feb 15.

39.

NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd.

Cancer Immunol Res. 2016 Apr;4(4):323-336. doi: 10.1158/2326-6066.CIR-15-0168. Epub 2016 Feb 10.

40.

TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.

Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, Chiocca EA, Kaur B, Caligiuri MA, Yu J.

Cancer Res. 2015 Dec 15;75(24):5273-82. doi: 10.1158/0008-5472.CAN-15-0894. Epub 2015 Dec 2.

41.

The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.

Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A, Caligiuri MA, Croce CM, Li L, Garzon R, Li C, Baiocchi RA, Marcucci G.

Leukemia. 2016 Apr;30(4):789-99. doi: 10.1038/leu.2015.308. Epub 2015 Nov 5.

PMID:
26536822
42.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd.

J Immunol. 2015 Sep 1;195(5):1995-2005. doi: 10.4049/jimmunol.1400084. Epub 2015 Aug 3.

43.

Rapid Column-Free Enrichment of Mononuclear Cells from Solid Tissues.

Scoville SD, Keller KA, Cheng S, Zhang M, Zhang X, Caligiuri MA, Freud AG.

Sci Rep. 2015 Jul 30;5:12490. doi: 10.1038/srep12490.

44.

Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.

Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, Blum W, Marcucci G, Caligiuri MA.

Leukemia. 2015 Dec;29(12):2382-9. doi: 10.1038/leu.2015.147. Epub 2015 Jun 19.

PMID:
26172401
45.

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.

Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso JC 3rd, Kaur B, Caligiuri MA, Yu J.

Sci Rep. 2015 Jul 9;5:11483. doi: 10.1038/srep11483.

46.

Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia.

Sood R, Hansen NF, Donovan FX, Carrington B, Bucci D, Maskeri B, Young A, Trivedi NS, Kohlschmidt J, Stone RM, Caligiuri MA, Chandrasekharappa SC, Marcucci G, Mullikin JC, Bloomfield CD, Liu P.

Leukemia. 2016 Feb;30(2):501-4. doi: 10.1038/leu.2015.141. Epub 2015 Jun 15. No abstract available.

47.

Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.

Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, Garzon R, Caligiuri MA, Bloomfield CD, Marcucci G.

Leukemia. 2015 Nov;29(11):2143-53. doi: 10.1038/leu.2015.139. Epub 2015 Jun 9.

48.

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA.

Clin Cancer Res. 2015 Sep 15;21(18):4055-61. doi: 10.1158/1078-0432.CCR-15-0304. Epub 2015 May 21.

49.

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.

Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G.

Leukemia. 2015 Oct;29(10):1981-92. doi: 10.1038/leu.2015.106. Epub 2015 May 14.

50.

Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome.

Wong HK, Gibson H, Hake T, Geyer S, Frederickson J, Marcucci G, Caligiuri MA, Porcu P, Mishra A.

J Invest Dermatol. 2015 Aug;135(8):2084-2092. doi: 10.1038/jid.2015.116. Epub 2015 Mar 25.

Supplemental Content

Loading ...
Support Center